Headache: Editorial review

Current Opinion in Neurology

Volumn 18, Issue 3, 2005, Pages 279-282

  Diener, Hans Christoph ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN; CYCLOOXYGENASE 2 INHIBITOR; ELETRIPTAN; FLUNARIZINE; METOCLOPRAMIDE; MIRTAZAPINE; ROFECOXIB; SEROTONIN AGONIST; SEROTONIN RECEPTOR; SUMATRIPTAN; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; ZOLMITRIPTAN;

BRAIN BLOOD FLOW; CLINICAL TRIAL; CLUSTER HEADACHE; COMORBIDITY; DEPRESSION; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; HEADACHE; HEMIPLEGIA; HUMAN; MIGRAINE; NONHUMAN; TENSION HEADACHE; CLASSIFICATION;

HEADACHE; HUMANS;

EID: 20444477403     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wco.0000169745.21912.d7     Document Type: Editorial

References (55)

1. Goadsby PJ, Lipton RB, Ferrari MD. Migraine: current understanding and treatment. N Engl J Med 2002; 346:257-270.
2. Silberstein SD. Migraine. Lancet 2004; 363:381-391.
3. Ferrari MD, Roon Ki, Lipton RB, Goadsby P. Oral triptans (serotonin 5-HT(1B/ 1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358:1668-1675.
4. Velentgas P, Cole JA, Mo J, Sikes CR, Walker AM. Severe vascular events in migraine patients. Headache 2004; 44:642-651.
5. Hall G, Brown M, Mo J, MacRae K. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 2004; 62:563-568.
6. Dodick D, Lipton R, Martin V, et al. Triptan Cardiovascular Safety Expert Panel. Consensus statement: cardiovascular safety profile of triptans (5-HT̂ agonists) in the acute treatment of migraine. Headache 2004; 44:414-425.
7. Dodick D, Martin V, Smith T, Silberstein S. Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache 2004; 44(Suppl 1):S20-S30.
8. Silberstein SD. The US Headache Consortium. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommitee of the American Academy of Neurology. Neurology 2000; 55:754-763.
9. Brandes J, Saper J, Diamond M, et al. MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004; 291:965-973.
10. Silberstein SD, Neto W, Schmitt J, Jacobs D. MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004; 61:490-495.
11. Diener HC, Tfelt-Hansen P, Dahlof C, et al. On behalf of the MIGR-003 Study Group. Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004; 251:943-950.
12. May A, Bahra A, Buchel C, et al. PET and MRA findings in cluster headache and MRA in experimental pain. Neurology 2000; 55:1328-1335.
13. Goadsby PJ. Migraine-pathogenetic concepts. In: Guidetti V, Russell G, Sillanpaa M, Winner P, editors. Headache and migraine in childhood and adolescence. London: Martin Dunitz; 2002. pp. 159-168.
14. May A, Bahra A, Buchel C, et al. Hypothalamic activation in cluster headache attacks. Lancet 1998; 352:258-275.
15. May A, Goadsby PJ. Neuroimaging of cluster headache. In: Diesen J, Tfelt-Hansen P, Welch KMA, editors. The headaches, 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2000. pp. 703-708.
16. Goadsby PJ, May A. PET demonstration of hypothalamic activation in cluster headache. Neurology 1999; 52:1522.
17. Leone M, Franzini A, D'Amico D, et al. Stereotactic electrode implant in inferior posterior hypothalamic gray matter to relieve intractable chronic cluster headache: the first reported case. Neurology 2001; 56(Suppl 3):A218.
18. Franzini A, Ferroli P, Leone M, Broggi G. Stimulation of the posterior hypothalamus for treatment of chronic intractable cluster headaches: first reported series. Neurosurgery 2003; 52:1095-1101.
19. Leone M, Franzini A, Broggi G, Bussone G. Hypothalamic deep brain stimulation for intractable chronic cluster headache: a 3-year follow up. J Neurol Sci 2003; 24(Suppl 2):143-145.
20. Jurkat-Rott K, Freilinger T, Dreier J, et al. Variability of familial hemiplegic migraine with novel A1A2 Na+/K+-ATPase variants. Neurology 2004; 62:1857-1861.
21. Vanmolkot K, Kors E, Hottenga J, et al. Novel mutations in the Na+, K+-ATPase pump gene ATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions. Ann Neurol 2003; 54:360-366.
22. De Fusco M, Marconi R, Silvestri L, et al. Haploinsufficiency of ATP1A2 encoding the Na/K pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nat Genet 2003; 33:192-196.
23. Swoboda K, Kanavakis E, Xaidara A, et al. Alternating hemiplegia of childhood or familial hemiplegic migraine? A novel ATP1A2 mutation. Ann Neurol 2004; 55:884-887.
24. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol 2004; 55:27-36.
25. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against development of cutaneous allodynia. Ann Neurol 2004; 55:19-26.
26. Mathew NT, Kailasam J, Meadors L. Early treatment of migraine with rizatriptan: a placebo-controlled study. Headache 2004; 44:669-673.
27. Cady RK, Lipton RB, Hall C, et al. Treatment of mild headache in disabled migraine sufferers: results of the Spectrum study. Headache 2000; 20:792-797.
28. Cady RK, Sheftell F, Lipton RB, et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin Ther 2000; 22:1035-1048.
29. Mathew N. Early intervention with almotriptan improves sustained pain-free response in acute migraine. Headache 2003; 43:1075-1079.
30. Scholpp J, Schellenberg R, Moeckesch B, Banik N. Early treatment of a migraine attack while pain is still mild increases the efficacy of sumatriptan. Cephalalgia 2004; 24:925-933.
31. Katsarava Z, Schneeweiss S, Kurth T, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 2004; 62:788-790.
32. Woods RP, Iacoboni M, Mazziotta JC. Bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med 1994; 331:1689-1692.
33. Bates D, Ashford E, Dawson R, et al. Subcutaneous sumatriptan during the migraine aura. Neurology 1994; 44:1587-1592.
34. Diesen J, Diener HC, Schoenen J, Hettiarachchi J. No effect of eletriptan administration during the aura phase of migraine. Eur J Neurol 2004; 11:671-677.
35. Diamond M, Hettiarachchi J, Hilliard B, et al. Effectiveness of eletriptan in acute migraine: primary care for Excedrin nonresponders. Headache 2004; 44:209-216.
36. Lipton R, Bigal M, Goadsby P. Double-blind clinical trials of oral triptans vs other classes of acute migraine medication: a review. Cephalalgia 2004; 24:321-332.
37. Diener HC, Eikermann A, Gessner U, et al. Efficacy of 1,000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms. Eur Neurol 2004; 52:50-56.
38. Thomas HM, Kudrow DB, Ashford E, et al. A phase III multicentre, randomised, double-blind, parallel-group study of valdecoxib 40 mg vs placebo in patients with multiple moderate or severe acute migraine headaches with and without aura [abstract]. Cephalalgia 2003; 23:697.
39. Silberstein S, Tepper S, Brandes J, et al. Randomised placebo-controlled trial of rofecoxib in the acute treatment of migraine. Neurology 2004; 62:1552-1557.
40. Hamalainen ML, Hoppu K, Santavuori P. Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Neurology 1997; 48:1100-1103.
41. Winner P, Saper JR, Nett R, et al. Sumatriptan nasal spray in the acute treatment of migraine in adolescent migraineurs. Pediatrics 1999; 104:694-695.
42. Korsgaard AG. The tolerability, safety and efficacy of oral sumatriptan 50 mg and 100 mg for the acute treatment of migraine in adolescents. Cephalalgia 1995; 16:98.
43. Rothner A, Edwards K, Kerr L, et al. Efficacy and safety of naratriptan tablets in adolescent migraine. J Neurol Sci 1997; 150:S106.
44. Winner P, Lewis D, Visser H, et al. Rizatriptan Adolescent Study Group. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. Headache 2002; 42:49-55.
45. Ahonen K, Hamalainen M, Rantala H, Hoppu K. Nasal sumatriptan is effective in treatment of migraine attacks in children: A randomized trial. Neurology 2004; 62:883-887.
46. Bahra A, Goadsby P. Diagnostic delays and mis-management in cluster headache. Acta Neurol Scand 2004; 109:175-179.
47. Diamond S, Baltes BJ. Chronic tension headache treated with amitriptyline: a double-blind study. Headache 1971; 11:110-116.
48. Göbel H, Hamouz V, Hansen C, et al. Chronic tension-type headache: amitriptyline reduces clinical headache-duration and experimental pain sensitivity but does not alter pericranial muscle activity readings. Pain 1994; 59:241-249.
49. Pfaffenrath V, Diener HC, Isler H, et al. Efficacy and saftey of amitriptylineoxide in the treatment of chronic tension-type headache. A multi-center double-blind study vs. amitriptyline and placebo. In: Diesen J, Schoenen J, editors. Tension-type headache. Classification, mechanisms and treatment. New York: Raven Press; 1993. pp. 269-274.
50. Bendtsen L, Jensen R, Olesen J. A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psychiatry 1996; 61:285-290.
51. Holroyd K, Labus J, O'Donnell F, Cordingley G. Treating chronic tension-type headache not responding to amitriptyline hydrochloride with paroxetine hydrochloride: a pilot evaluation. Headache 2003; 43:999-1004.
52. Ashina S, Bendtsen L, Jensen R. Analgesic effect of amitriptyline in chronic tension-type headache is not directly related to serotonin reuptake inhibition. Pain 2004; 108:108-114.
53. Bendtsen L, Jensen R. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. Neurology 2004; 62: 1706-1711.
54. Schulte-Mattler W, Krack P, for the BoNTTH Study Group. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain 2004; 109:110-114.
55. Padberg M, de Bruijn SF, de Haan RJ, Tavy DL. Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial. Cephalalgia 2004; 24:675-680.